Abstract
Alzheimer’s disease (AD) is a looming public health crisis that currently lacks an effective treatment. Noninvasive Brain Stimulation (NBS), particularly transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), offers a promising alternative approach to pharmacological interventions for an increasing number of neurological and psychiatric conditions. The aim of this review is summarize data from therapeutic trials of NBS in AD and other dementing illnesses.
Despite the potential of NBS, there is limited theoretical framework and a lack of guidelines for its applications to AD. Several published clinical trials failed to report key parameters of the interventions thus limiting the utility of the study to assess efficacy and safety. Our review concludes with some suggestions for future studies aimed to advance research into NBS as a potential treatment for the symptoms and disabilities caused by AD and to enable comparison of results across trials. Ultimately, appropriately powered, and controlled, multi-site randomized clinical trials will be needed to evaluate the therapeutic potential of NBS in AD.Keywords: Alzheimer's disease, transcranial magnetic stimulation, TMS, tDCS, dementia, noninvasive brain stimulation, NBS.
Current Alzheimer Research
Title:Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease
Volume: 14 Issue: 4
Author(s): Irene Gonsalvez, Roey Baror, Peter Fried, Emiliano Santarnecchi and Alvaro Pascual-Leone
Affiliation:
Keywords: Alzheimer's disease, transcranial magnetic stimulation, TMS, tDCS, dementia, noninvasive brain stimulation, NBS.
Abstract: Alzheimer’s disease (AD) is a looming public health crisis that currently lacks an effective treatment. Noninvasive Brain Stimulation (NBS), particularly transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), offers a promising alternative approach to pharmacological interventions for an increasing number of neurological and psychiatric conditions. The aim of this review is summarize data from therapeutic trials of NBS in AD and other dementing illnesses.
Despite the potential of NBS, there is limited theoretical framework and a lack of guidelines for its applications to AD. Several published clinical trials failed to report key parameters of the interventions thus limiting the utility of the study to assess efficacy and safety. Our review concludes with some suggestions for future studies aimed to advance research into NBS as a potential treatment for the symptoms and disabilities caused by AD and to enable comparison of results across trials. Ultimately, appropriately powered, and controlled, multi-site randomized clinical trials will be needed to evaluate the therapeutic potential of NBS in AD.Export Options
About this article
Cite this article as:
Gonsalvez Irene, Baror Roey, Fried Peter, Santarnecchi Emiliano and Pascual-Leone Alvaro, Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease, Current Alzheimer Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567205013666160930113907
DOI https://dx.doi.org/10.2174/1567205013666160930113907 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimers Disease Pharmacogenetics
Current Alzheimer Research Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Mechanisms of Protein Misfolding in Conformational Lung Diseases
Current Molecular Medicine Involvement of Gaucher Disease Mutations in Parkinson Disease
Current Protein & Peptide Science Neuroprotective effects of the securinine-analogues: identification of Allomargaritarine as a lead compound
CNS & Neurological Disorders - Drug Targets A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Tailored Multi-Target Agents. Applications and Design Considerations
Current Pharmaceutical Design Traumatic Brain Injury as a Risk Factor for Schizophrenia
Current Psychiatry Reviews In Silico Dynamic Molecular Interaction Networks for the Discovery of New Therapeutic Targets
Current Pharmaceutical Design Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases
Current Drug Therapy Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Synthesis, Molecular Docking, and Biological Evaluation of Benzimidazole Derivatives as Selective Butyrylcholinesterase Inhibitors
Current Alzheimer Research Cognitive Event-Related Potentials: Useful Clinical Information in Alzheimers Disease
Current Alzheimer Research Neuroprotective Effects of Lutein in the Retina
Current Pharmaceutical Design Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Transdermal Drug Delivery Systems and their Potential in Alzheimer’s Disease Management
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design